全文获取类型
收费全文 | 447篇 |
免费 | 17篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 10篇 |
妇产科学 | 2篇 |
基础医学 | 68篇 |
口腔科学 | 1篇 |
临床医学 | 19篇 |
内科学 | 16篇 |
皮肤病学 | 67篇 |
神经病学 | 130篇 |
特种医学 | 7篇 |
外科学 | 74篇 |
综合类 | 1篇 |
预防医学 | 11篇 |
眼科学 | 2篇 |
药学 | 36篇 |
肿瘤学 | 19篇 |
出版年
2024年 | 2篇 |
2023年 | 12篇 |
2022年 | 10篇 |
2021年 | 17篇 |
2020年 | 5篇 |
2019年 | 15篇 |
2018年 | 9篇 |
2017年 | 7篇 |
2016年 | 31篇 |
2015年 | 11篇 |
2014年 | 17篇 |
2013年 | 17篇 |
2012年 | 23篇 |
2011年 | 28篇 |
2010年 | 18篇 |
2009年 | 14篇 |
2008年 | 21篇 |
2007年 | 27篇 |
2006年 | 23篇 |
2005年 | 21篇 |
2004年 | 12篇 |
2003年 | 24篇 |
2002年 | 26篇 |
2001年 | 10篇 |
2000年 | 12篇 |
1999年 | 4篇 |
1998年 | 5篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 4篇 |
1994年 | 1篇 |
1993年 | 5篇 |
1992年 | 5篇 |
1991年 | 3篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 4篇 |
1986年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1980年 | 2篇 |
1977年 | 1篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有464条查询结果,搜索用时 15 毫秒
1.
The cytokine lymphotoxin (LT)α is known to play a role in B cell activation. As the engagement of the B cell antigen CD40 is known to lead to B cell proliferation and differentiation, we studied LTα expression in human B cells after CD40 ligation. We demonstrate that anti-CD40 monoclonal antibody (mAb) induces strong LTα mRNA and surface expression in human tonsil B cells. Induction of LTα mRNA and surface expression by CD40 ligation is inhibited by the protein tyrosine kinase (PTK) inhibitors herbimycin and genistein in a dose-dependent manner. The protein kinase C (PKC)-specific inhibitors sphingosine and bisindolylmaleimide caused negligible inhibition of anti-CD40-induced LTα mRNA and surface expression. No inhibition is observed with the protein kinase (PKA) inhibitors H89 and HA1004. Cross-linking of the transmembrane phosphatase CD45 to CD40 by using goat-anti-mouse F(ab')2 fragments strongly inhibits CD40-mediated LTα expression in human B cells, confirming the role of PTK activation in CD40-mediated induction of LTα expression. Inhibitors of the serine/threonine protein phosphatases PP1 and PP2A, okadaic acid and calyculin induce LTα mRNA expression. In contrast, cyclosporin A, an inhibitor of the serine/threonine phosphatase calcineurin has no effect on anti-CD40-induced LTα expression. These results suggest that induction of LTα expression in B cells following engagement of CD40 involves activation of protein tyrosine kinases. 相似文献
2.
3.
4.
Jonathan I. Silverberg Emma Guttman-Yassky Melinda Gooderham Margitta Worm Stephanie Rippon Sean O’Quinn René van der Merwe Nana Kragh Azra Kurbasic Andreas Wollenberg 《Annals of allergy, asthma & immunology》2021,126(5):576-583.e4
BackgroundAtopic dermatitis (AD) is associated with a substantial burden on quality of life (QoL).ObjectiveTo evaluate the effects of tralokinumab on health-related QoL in patients with moderate-to-severe AD using patient-reported outcomes.MethodsThis was a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study in adults with moderate-to-severe AD. The patients received subcutaneous tralokinumab or placebo (1:1:1:1) every 2 weeks for 12 weeks and class 3 topical corticosteroid cream or ointment at least once daily from the run-in to end of follow-up. Patient-reported outcome end points were change from baseline to week 12 in the Dermatology Life Quality Index (dermatology life quality index (DLQI); prespecified secondary objective), the Short Form 36 Health Survey (SF-36) version 2, and sleep interference numeric rating scale score (prespecified exploratory objectives).ResultsA total of 204 patients were randomized to placebo (n = 51) or tralokinumab (45 mg, n = 50; 150 mg, n = 51; 300 mg, n = 52). Tralokinumab 300 mg every 2 weeks improved total Dermatology Life Quality Index vs placebo at week 12 (placebo-adjusted mean change, ?3.51 [95% confidence interval, ?6.00 to ?1.02]). At week 12, both the mental component summary (4.23 [0.98-7.47]) and the physical component summary (4.26 [1.83-6.69]) and all 8 domains of the Short Form 36 Health Survey were improved in patients treated with tralokinumab 300 mg vs placebo. Sleep interference was improved at week 12 with all tralokinumab doses vs placebo.ConclusionTralokinumab improved health-related QoL in patients with moderate-to-severe atopic dermatitis, providing further evidence of the value of targeting interleukin-13 in such patients.Trial RegistrationClinicalTrials.gov identifier: NCT02347176; https://clinicaltrials.gov/ct2/show/NCT02347176. 相似文献
5.
6.
7.
8.
Advanced urothelial carcinoma of the bladder is an aggressive tumor with a poor prognosis. Besides surgical therapy, classical chemotherapy with platinum compounds is the mainstay of advanced bladder cancer treatment. In recent years, immune modulating therapies have come into the focus of clinical trials. This review provides an overview of the biological mechanisms and immuno-oncological drugs that are currently being analyzed in clinical trials as well as established standard therapies. 相似文献
9.
10.
Thomas Pyka Shozo Okamoto Marielena Dahlbender Robert Tauber Margitta Retz Matthias Heck Nagara Tamaki Markus Schwaiger Tobias Maurer Matthias Eiber 《European journal of nuclear medicine and molecular imaging》2016,43(12):2114-2121